SecBot SecBot
6-K ·Filed Jul 30, 2026

MESO

MESOBLAST LTD
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001345099-26-000072
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong first-year Ryoncil revenue validates commercial execution and supports the pipeline expansion into larger indications (adult SR-aGvHD, DMD, CLBP, LVAD). Traders should watch for enrollment updates in the adult SR-aGvHD trial and the DMD trial, as well as the CLBP Phase 3 data readout and the modular BLA review for rexlemestrocel-L. The CAR technology license adds optionality in autoimmune indications but is early-stage.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

MESO drug pipeline →

rexlemestrocel-L

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$14.55
T+0 close · Jul 30, 2026 · via day close
Latest settled
−15.60%
T+60 · $12.28
Vs SPY
−18.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $14.55entry
  2. T+1 · 4mo ago −2.61%α −3.32% · $14.17
  3. T+5 · 3mo ago +7.35%α +3.73% · $15.62
  4. T+20 · 3mo ago +24.95%α +20.98% · $18.18
  5. T+60 · 25d ago −15.60%α −18.07% · $12.28
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and US$115M for the first full year post-FDA approval, with US$103M cash at quarter end. Operational milestones include commencement of the adult SR-aGvHD label extension trial, IND clearance for Duchenne muscular dystrophy, and achievement of the 300-patient enrollment target in the pivotal Phase 3 chronic low back pain trial. The company also received a BLA filing number for rexlemestrocel-L in LVAD patients and acquired a CAR technology license.

Key Facts

  • Ryoncil net revenue Q4 FY2026: US$36 million
  • Ryoncil net revenue first full year post-FDA approval: US$115 million (US$66.5M in H2)
  • Cash and cash equivalents at June 30, 2026: US$103 million
  • Net operating cash spend full year: US$43.8 million (US$13.4M in H2)
  • Registration trial for Ryoncil label extension into adults with SR-aGvHD commenced and enrolling
  • FDA IND clearance received for Ryoncil in ambulatory children aged 5-9 with Duchenne muscular dystrophy
  • Target of at least 300 patients treated in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain achieved
  • BLA filing number received from FDA for rexlemestrocel-L in prevention of GI bleeding in LVAD patients
  • Acquired exclusive worldwide license to a patented CAR technology platform for MSC enhancement

Financial Impact

Ryoncil generated US$115M in annual net revenue in its first full launch year; operating cash burn of US$43.8M; cash position of US$103M provides ~11 quarters of runway at current burn rate

revenuecashoperating cash flow

Risk Factors

  • Clinical trial enrollment and data readout risks for adult SR-aGvHD, DMD, and CLBP trials
  • Regulatory approval uncertainty for rexlemestrocel-L BLA in LVAD indication
  • Competition from other cell therapies and biologics in inflammatory diseases
  • Cash burn may require future financing if revenue growth slows or pipeline milestones are delayed

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001345099-26-000072
Document: form6-kxpressreleasecoverf.htm0001345099-26-000072
Document: 0001345099-26-000072-index-headers.html0001345099-26-000072
Document: 0001345099-26-000072-index.html0001345099-26-000072
Document: 0001345099-26-000072.txt0001345099-26-000072

Track record

25 reports on MESO

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +15.67% at T+5 after the Jul 9, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026